We are live on ! Find out more
SRPT icon

Sarepta Therapeutics

484 hedge funds and large institutions have $14B invested in Sarepta Therapeutics in 2024 Q2 according to their latest regulatory filings, with 119 funds opening new positions, 176 increasing their positions, 126 reducing their positions, and 45 closing their positions.

New
Increased
Maintained
Reduced
Closed

164% more first-time investments, than exits

New positions opened: 119 | Existing positions closed: 45

100% more call options, than puts

Call options by funds: $650M | Put options by funds: $325M

53% more capital inflows, than outflows

Capital inflows: $2.09B | Capital outflows: $1.36B

40% more repeat investments, than reductions

Existing positions increased: 176 | Existing positions reduced: 126

17% more funds holding

Funds holding: 413 → 484 (+71)

7% more funds holding in top 10

Funds holding in top 10: 15 → 16 (+1)

5.31% more ownership

Funds ownership: 88.6% → 93.91% (+5.3%)

Holders
484
Holders Change
+71
Holders Change %
+17.19%
% of All Funds
6.97%
Holding in Top 10
16
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+6.67%
% of All Funds
0.23%
New
119
Increased
176
Reduced
126
Closed
45
Calls
$650​M
Puts
$325​M
Net Calls
+$325​M
Net Calls Change
-⁠$127​M

SRPT Hedge Fund Activity: Q2 2024 in Review

484 of the 6,945 institutional investors tracked by Wall St. Rank reported a position in Sarepta Therapeutics (SRPT) for Q2 2024, worth a combined $14B — up 30% from $10.8B a quarter earlier.

Buyers outnumbered sellers: 119 funds opened new SRPT positions and 45 closed out — a net gain of 74 holders — while 176 added to existing stakes and 126 trimmed.

The largest buyer was BlackRock, adding an estimated $561M. The largest seller was Avoro Capital Advisors, cutting an estimated $173M.

  • 484 institutional investors held Sarepta Therapeutics (SRPT) as of Q2 2024, up from 413 in Q1 2024.
  • Funds reported $14B of Sarepta Therapeutics stock for Q2 2024, up 30% quarter-over-quarter.
  • 119 funds opened new Sarepta Therapeutics positions in Q2 2024 and 45 closed out, a net change of +74 holders.
  • The largest Sarepta Therapeutics buyer in Q2 2024 was BlackRock, an estimated $561M added.
  • The largest Sarepta Therapeutics seller in Q2 2024 was Avoro Capital Advisors, an estimated $173M sold.

Based on aggregated 13F filings for Q2 2024.